Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection

Vaccine

Volumn 22, Issue 25-26, 2004, Pages 3495-3502

  Warfield, Kelly L ^a   Swenson, Dana L ^a   Negley, Diane L ^a   Schmaljohn, Alan L ^a   Aman, M Javad ^b   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Clinical Research Management   (United States)

Author keywords

Immunity; Marburg virus; Vaccine; Virus like particle

Indexed keywords

CD4 ANTIGEN; CORD FACTOR; INACTIVATED VIRUS VACCINE; MARBURG VIRUS ANTIBODY; PHOSPHORYL LIPID A; TREHALOSE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; GUINEA PIG; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; IN VITRO STUDY; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS ACTIVATION; VIRUS CULTURE; VIRUS HEMORRHAGIC FEVER; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EBOLAVIRUS; GUINEA PIGS; LYMPHOCYTE COUNT; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICROSCOPY, ELECTRON; NEUTRALIZATION TESTS; PLAQUE ASSAY; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 4043050913     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.01.063     Document Type: Article

References (43)

1. Feldmann H., Klenk H.D., Sanchez A. Molecular biology and evolution of filoviruses. Arch. Virol. Suppl. 7:1993;81-100
2. Feldmann H., Klenk H.D. Marburg and Ebola viruses. Adv. Virus Res. 47:1996;1-52
3. Martini GA, Seigert R, editor. Marburg virus disease. Berlin: Springer-Verlag; 1971.
4. Smith D.H., Johnson B.K., Isaacson M., Swanapoel R., Johnson K.M., Killey M., et al. Marburg-virus disease in Kenya. Lancet. 1(8276):1982;816-820
5. Belanov E.F., Muntianov V.P., Kriuk V.D., Sokolov A.V., Bornotov N.I., Plankov O.V., et al. Survival of Marburg virus infectivity on contaminated surfaces and in aerosols. Vopr. Virusol. 41:1996;32-34
6. Frolov VGAG, M. Stability of Marburg virus to lyophilization process and subsequent storage at different temperatures. Vopr. Virusol. 1996;41:275-7.
7. Alibek K, Handelsman S, Biohazard: random house. New York, NY, USA; 1999.
8. Stroher U., West E., Bugany H., Klenk H.D., Schnittler H.J., Feldmann H. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75(22):2001;11025-11033
9. Gibb TR, Norwood Jr DA, Woollen N, Henchal EA. Viral replication and host gene expression in alveolar macrophages infected with Ebola virus (Zaire strain). Clin Diagn Lab Immunol 2002;9(1):19-27.
10. Bosio C.M., Aman M.J., Grogan C., Hogan R., Ruthel G., Negley D., et al. Ebola and marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188(11):2003;1630-1638
11. Mahanty S., Hutchinson K., Agarwal S., McRae M., Rollin P.E., Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170(6):2003;2797-2801
12. Feldmann H., Bugany H., Mahner F., Klenk H.D., Drenckhahn D., Schnittler H.J. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70(4):1996;2208-2214
13. Steinman R.M. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt. Sinai. J. Med. 68(3):2001;106-166
14. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5(4):423-6.
15. Leroy E.M., Baize S., Volchkov V.E., Fisher-Hoch S.P., Georges-Courbot M.C., Lansoud-Soukate J., et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 355(9222):2000;2210-2215
16. Leroy E.M., Baize S., Debre P., Lansoud-Soukate J., Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin. Exp. Immunol. 124(3):2001;453-460
17. Baize S., Leroy E.M., Georges A.J., Georges-Courbot M.C., Capron M., Bedjabaga I., et al. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128(1):2002;163-168
18. Hevey M., Negley D., Geisbert J., Jahrling P., Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 239(1):1997;206-216
19. Hevey M., Negley D., Pushko P., Smith J., Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 251(1):1998;28-37
20. Hevey M., Negley D., VanderZanden L., Tammariello R.F., Geisbert J., Schmaljohn C., et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine. 20(3-4):2001;586-593
21. Ignatyev G.M., Agafonov A.P., Streltsova M.A., Kashentseva E.A. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J. Biotechnol. 44(1-3):1996;111-118
22. Ignatev G.M., Agafonov A.P., Strel'tsova M.A., Kuz'min V.A., Mainagasheva G.I., Spirin G.V., et al. A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus. Vopr. Virusol. 36:1991;421-423
23. Riemenschneider J., Garrison A., Geisbert J., Jahrling P., Hevey M., Negley D., et al. Comparison of individual and combination DNA vaccines for B anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 21(25-26):2003;4071-4080
24. Johnson J.E., Chiu W. Structures of virus and virus-like particles. Curr. Opin. Struct. Biol. 10(2):2000;229-235
25. Wagner R., Shao Y., Wolf H. Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine. Vaccine. 17(13-14):1999;1706-1710
26. Palker T.J., Monteiro J.M., Martin M.M., Kakareka C., Smith J.F., Cook J.C., et al. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine. 19(27):2001;3733-3743
27. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93(4):2001;284-292
28. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, Geisbert TW, et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002;195(5):593-602.
29. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. U.S.A. 100(26):2003;15889-15894
30. Swenson DL, Warfield KL, Kuehl K, Larsen T, Hevey MC, Schmaljohn A, et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol, 2004;40(1):27-31.
31. Rao, M, Bray, M, Alving, CR, Jahrling, P, Matyas, GR. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol 2002;76(18):9176-85.
32. Wilson J.A., Hevey M., Bakken R., Guest S., Bray M., Schmaljohn A.L., et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 287(5458):2000;1664-1666
33. Xu L., Sanchez A., Yang Z., Zaki S.R., Nabel E.G., Nichol S.T., et al. Immunization for Ebola virus infection. Nat. Med. 4(1):1998;37-42
34. Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001;75(6):2660-4.
35. Hevey M., Negley D., Schmaljohn A. Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virology. 314(1):2003;350-357
36. Hart M.K. Vaccine research efforts for filoviruses. Int. J. Parasitol. 33:2003;583-595
37. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 408(6812):2000;605-609
38. Price D.A., Klenerman P., Booth B.L., Phillips R.E., Sewell A.K. Cytotoxic T lymphocytes, chemokines and antiviral immunity. Immunol. Today. 20(5):1999;212-216
39. Vanderzanden L., Bray M., Fuller D., Roberts T., Custer D., Spik K., et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 246(1):1998;134-144
40. Ignatev G.M. Immune response to filovirus infections. Curr. Top. Microbiol. Immunol. 235:1999;205-217
41. Takada A., Watanabe S., Okazaki K., Kida H., Kawaoka Y. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J. Virol. 75(5):2001;2324-2330
42. Takada A., Feldmann H., Ksiazek T.G., Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77(13):2003;7539-7544
43. Takada A., Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol. 13(6):2003;387-398